Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans.
Clinical pharmacokinetics November 1, 2025 Léa Comin, Solène Marie, Moreno Ursino et al.
A pharmacokinetic model built from whole-body dynamic PET scans after a microdose of radiolabeled glyburide in 16 healthy people describes the drug's biodistribution and yields parameters consistent with standard blood-based studies. The model included seven compartments, with two each for liver and kidneys. Rifampicin, a drug that can cause interactions, decreased liver distribution by 261%. The estimated central volume of distribution (3.6 L) and elimination rate (0.8 h-1) matched known glyburide pharmacokinetics, suggesting microdose PET data can be used to study whole-body drug distribution.